Abstract

This study investigated 12-year blood lipid trajectories and whether these trajectories are modified by smoking and lipid lowering treatment in older Russians. To do so, we analysed data on 9,218 Russian West-Siberian Caucasians aged 45–69 years at baseline participating in the international HAPIEE cohort study. Mixed-effect multilevel models were used to estimate individual level lipid trajectories across the baseline and two follow-up examinations (16,445 separate measurements over 12 years). In all age groups, we observed a reduction in serum total cholesterol (TC), LDL-C and non-HDL-C over time even after adjusting for sex, statin treatment, hypertension, diabetes, social factors and mortality (P<0.01). In contrast, serum triglyceride (TG) values increased over time in younger age groups, reached a plateau and decreased in older age groups (> 60 years at baseline). In smokers, TC, LDL-C, non-HDL-C and TG decreased less markedly than in non-smokers, while HDL-C decreased more rapidly while the LDL-C/HDL-C ratio increased. In subjects treated with lipid-lowering drugs, TC, LDL-C and non-HDL-C decreased more markedly and HDL-C less markedly than in untreated subjects while TG and LDL-C/HDL-C remained stable or increased in treatment naive subjects. We conclude, that in this ageing population we observed marked changes in blood lipids over a 12 year follow up, with decreasing trajectories of TC, LDL-C and non-HDL-C and mixed trajectories of TG. The findings suggest that monitoring of age-related trajectories in blood lipids may improve prediction of CVD risk beyond single measurements.

Introduction

Plasma lipid values are important modifiable risk factors of cardiovascular diseases [1]. According to the long-term used approach in preventive cardiology plasma total cholesterol
Lipid trajectories in elderly Russians

Materials and methods

Subjects

Participants in the Russian arm of the Health, Alcohol and Psychosocial Factors in Eastern Europe (HAPIEE) study were included in the analysis. The study sample comprised of men and women aged 45–69 at baseline living in two districts (Oktyabr'skiy and Kirovskiy) of the West-Siberian city of Novosibirsk, randomly samples from the electoral list stratified by 5-year age group and sex (response rate 61%). Details of the study protocol have been described elsewhere [12]; baseline characteristics of the subjects from the Russian part of the study have also been published previously [13, 14].

Anthropometric parameters, alcohol consumption, smoking status, history of dyslipidaemia and lipid-lowering treatment, history of cardiovascular and other chronic diseases, and socio-demographic parameters were assessed by trained nurses using a standardised protocol and questionnaire [12, 15]. Blood samples were drawn at fasting condition (at least 8 hours). Serum was stored at -80°C and analyses for lipids were conducted within one month period.
after samples collection. After the baseline examination in 2003–2005 (wave 1), participants were followed up by two subsequent waves in 2006–2008 (wave 2) and 2015–2017 (wave 3). After excluding a minority of subjects aged 70 years or older at baseline (N = 111) from the analysis, the final study group consisted of 9,218 subjects (16,445 measurements/observations).

The study was conducted according to the guidelines of the Declaration of Helsinki, and was approved by the ethics committee of the Research Institute of Internal and Preventive Medicine—Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences (protocol 1 from 14.mar.2002). Informed consent was obtained from all subjects involved in the study.

**Blood lipid analysis**

Blood lipid concentrations across three waves were measured in Laboratory of Biochemistry, Institute of Internal and Preventive Medicine. Serum lipid values were analysed enzymatically using kits from Thermo Fisher Scientific (total cholesterol–Cat. No. 981812; HDL-cholesterol–Cat. No. 981823; triglycerides–Cat. No. 981301; LDL-cholesterol (LDL-C) direct measurement–Cat. No. 981656; HDL/LDL calibrator–Cat. No. 981657, and LIPOTROL control–Cat. No. 981653) on a KoneLab 30i autoanalyser (Thermo Fisher Scientific Inc., USA).

For subjects with serum TG values below 4.5 mmol/L, LDL-C values were calculated using the Friedewald formula [16]. For few subjects with TG values above 4.5 mmol/L, LDL-C values were measured using a direct enzymatic method. Non-HDL-C values were calculated using the equation: Non-HDL-C = TC–HDL-C.

Internal quality control was applied daily on a permanent basis by a biochemical laboratory, with external quality control routinely provided by a Moscow Federal standardisation centre on an annual basis. Laboratory was standardised for lipid measurements under the framework of the HAPIEE study, the Centres for Disease Control (Atlanta, USA) and the Institute of Clinical and Experimental Medicine (Prague, Czech Republic).

**Statistical analysis**

In order to model trajectories of blood lipid values across three measurement waves over an average 12-year follow-up period, multilevel modelling (MLM) techniques were used. Specific measurement occasions at baseline, wave 2 and wave 3 were considered level 1 variables nested within study participants (level 2 variables). Both the intercept and slope were fitted as random effects, allowing individual differences in lipid concentrations at baseline and rate of change.

In order to distinguish between ageing and period/cohort effects, we separately modelled TC, LDL-C, HDL-C, TG as well as computed non-HDL-C and LDL-C/HDL-C trajectories over the 12-year follow-up period by 5-year birth cohorts. Estimates were unadjusted in model 1, adjusted for sex and lipid-lowering treatment (assessed in all three data collection waves) in model 2, and further adjusted for smoking (never-, ex-, current-smoker), BMI, alcohol consumption (non-drinkers, moderate drinkers, heavy drinkers: defined as >30 g/day for men and >15 g/day for women), education (primary, secondary, vocational, university), marital status (single, married/co-habiting), and CVD/all-cause mortality (identified by linkage with mortality-registry) in model 3. Slopes were calculated separately for male and female participants.

For sensitivity analysis, first, we recalculated trajectories only among subjects with available measurements of lipids across all three waves (N = 2,009). Second, we recalculated trajectories after exclusion of subjects who dropped out after baseline wave 1 and had no evidence of fatal outcome during follow-up period (N = 7,606).
All statistical analysis was carried out using MLwiN v3.01 software and accessed through Stata v13.1 by inputting the ‘runmlwin’ command [17]. P-values less than 0.05 were considered significant (calculated for trend).

Results

Descriptive characteristics of the sample

The general characteristics of the subjects evaluated across all three examinations are summarised in Table 1. Data on TC, LDL-C, HDL-C and TG were obtained from 9,218 participants at baseline, 3,442 subjects at wave 2 and 3,785 persons at wave 3, totalling 16,445 individual-level examinations. A total of 2,009 individuals were measured in all three waves (6,027 individual examinations). Waves 2 and 3 were conducted on average 3.2 and 12.3 years, respectively, after the baseline examination; the age range of participants increased from 45–69 years at baseline to 56–83 years at wave 3; however, the proportion of participants receiving lipid-lowering treatment (mostly statins) over time increased substantially between wave 1 and wave 3 from 23.8% to 47.1% among those aware of dyslipidemia.

Overall lipid trajectories

Notable changes in serum lipids were observed over the follow-up period. In simple cross-sectional analysis by wave of measurement, we observed a moderate decrease in mean TC, LDL-C and HDL-C values between baseline and both follow-up phases for the entire population in both men and women. In contrast, mean TG values remained similar across all three examinations (Table 1).

Table 2 and Fig 1 show the unadjusted individual-level trajectories of blood lipids during follow up for all 5-year age groups. For in TC and LDL-C, the slopes of decline in concentrations were more pronounced in older cohorts, and this pattern was consistent with estimates adjusted for sex and lipid lowering treatment (Table 3) and with multivariable adjusted models (Table 4).

Changes in HDL-C over time were less pronounced compared to TC and LDL-C and the decline in HDL-C concentrations was similar in all 5-year groups (Tables 2–4; Fig 1). In contrast, TG values increased over the follow up in the younger cohort and decreased in the cohort of subjects over 60 years of age (Tables 2–4; Fig 1). For more details about the lipid trajectories in 5-years sub-group, see S1–S6 Figs.

As a sensitivity analysis, we repeated our assessment only in subjects whose serum lipids were obtained across all 3 waves (‘complete cases’, N = 2,009). The direction and slope of the trajectories virtually did not change (data are shown in S1 and S2 Tables).

Additionally, we repeated calculations in a subsample of 7,606 participants after exclusion of subjects who dropped out after baseline examination and did not die during follow-up. The direction and slope of the trajectories were similar to the patterns in the total sample (data are shown in S3 and S4 Tables).

Effects of smoking status

Fig 2 shows the influence of smoking status on trajectories (ever- vs. never-smokers, adjusted for sex, lipid-lowering medication, and centred age at 58 years). At baseline and throughout the follow-up period, TC values remained comparable, exhibiting a similar decreasing slope in ever-smokers and never-smokers. Concentrations of LDL-C and non-HDL-C in smokers were lower at baseline and decreased less markedly than in non-smokers; in contrast, levels of HDL-C were higher among smokers at baseline but decreased more markedly. At baseline and throughout follow-up, TG was higher in smokers; trajectories were divergent, remaining
relatively stable in smokers while decreasing in never-smokers. LDL-C/HDL-C ratios were lower at baseline in smokers; trajectories were in opposition, increasing in ever-smokers and remained stable in never-smokers. These contrasting TG and LDL-C/HDL-C trajectories seem to have been further influenced by the age-cohort effect, with a more pronounced increase among smokers observed in subjects under 60 years of age and a decrease in those over 60 years of age (more details summarised within the S7–S12 Figs).

Effects of lipid-lowering therapy

Fig 3 and S13 Fig show the differences in trajectories between subjects treated with lipid-lowering drugs and treatment-naïve subjects, adjusted for sex and centred age (58 years). As
expected, in subjects treated with lipid-lowering drugs, TC baseline values were lower; however, LDL-C, non-HDL-C and HDL-C values were similar, while TG values and LDL-C/HDL-C ratios were higher than in treatment-naïve subjects. The declines in all four main lipid categories over time (slope) in subjects given medication were much more pronounced than in untreated persons. For TG and LDL-C/HDL-C, trajectories were in opposite directions, decreasing in lipid-lowering-treated individuals and remaining stable or increasing in treatment-naïve subjects. More detailed comparison between the treated and untreated subjects within the different age subgroups are summarised within the S13–S18 Figs.

Discussion

In this Russian population-based urban cohort aged 45–69 years old at baseline, we observed a reduction with aging in plasma levels of total, LDL- and HDL-cholesterol at individual level over 12 year follow up in all age groups. This decrease was more pronounced in subjects using cholesterol lowering medication and was more distinct for total cholesterol than to LDL-C. In contrast, plasma triglyceride levels increased with advancing age, with peak values observed in subjects in the age category of 55–59 years. Across all three examinations, the mean plasma lipid values were higher (lower in the case of HDL-cholesterol) than the values recommended by European cardiology societies [3]. As summarised previously, plasma concentrations of total and LDL-C in this population were 6.3 and 4.1 mmol/L, respectively [14].

This study has several limitations. First, we cannot exclude the possibility of differential cohort attrition due to increased CVD mortality risk in subjects with dyslipidaemia and/or
due to increased non-CVD mortality among those with extreme lipids decline. However, we adjusted the estimates for both total and CVD mortality. Importantly, our results were similar in full initial sample and two sensitivity analyses in ‘complete case’ sample (participants of all three waves) and after excluding persons who dropped out since baseline. This fact suggests that attrition did not affect the observed trajectories substantially.

Second, the baseline response rate was moderate (61%), which can affect the mean lipid levels, as non-participants in epidemiological studies usually have healthier risk factor profile. In addition, the study did not include young adults who may have otherwise exhibited different lipid trajectories.
On the other hand, results were similar (concerning the direction and slope of the trajectories) when we repeated our assessment only in subjects whose serum lipids were known across all 3 waves.

We cannot fully exclude the impact of a range of potential confounding factors. However, we have adjusted the final models for the most common confounders (sex, age, lipid-lowering treatment, smoking, BMI, alcohol consumption, education, marital status, CVD/all-cause mortality); and also have stratified analysis by sex and by 5-year age groups. Few additional models were calculated controlling the lipid curves for basal fruits or vegetables intake (by terciles) with centered value of total energy intake (10.6 MJ/day), and for leisure time physical activity (3 categories) (data not shown). These additional adjustments did not substantially change the trajectories direction. The specific consideration of nutrition or physical activity effect on lipid changes might be a subject of separate analysis (taking into account restrictions in data available) and it is not in the scope of present paper. Also we have not information on specific medications (except of class), but it is unlikely that separate drugs might affect the average lipid level beyond the general effect of lipid-lowering treatment.

Finally, this study only included participants from one large city, and these results may not be generalisable to the whole country. However, the trends of risk factors in Novosibirsk and rates of CVD mortality in the region are close to those seen the Russian Federation across the last 30 years (Rosstat), so Novosibirsk can be seen as a useful case study mirroring at some extent the national pattern.

### Table 3. Baseline total cholesterol, LDL-C, HDL-C and triglycerides (intercept) and change in LDL-C, HDL-C and triglycerides per year (slope) in the 5-yr cohorts (adjusted*).

| Age range in W1 | TC | LDL-C | HDL-C | TG |
|----------------|----|-------|-------|----|
|                | coeff. | SE | p-value | coeff. | SE | p-value |
| Intercept      |        |    |         |        |    |         |
| 45–49 (ref)    | 5.64  | 0.033 | <0.001 | 3.54  | 0.030 | <0.001 |
| 50–54          | 0.239 | 0.041 | <0.001 | 0.197 | 0.037 | <0.001 |
| 55–59          | 0.362 | 0.040 | <0.001 | 0.298 | 0.036 | <0.001 |
| 60–64          | 0.514 | 0.042 | <0.001 | 0.456 | 0.037 | <0.001 |
| 65–69          | 0.447 | 0.040 | <0.001 | 0.397 | 0.036 | <0.001 |
| Slope          |        |    |         |        |    |         |
| 45–49 (ref)    | -0.024 | 0.004 | <0.001 | -0.012 | 0.004 | 0.020 |
| 50–54          | -0.026 | 0.005 | <0.001 | -0.021 | 0.004 | <0.001 |
| 55–59          | -0.047 | 0.005 | <0.001 | -0.041 | 0.004 | <0.001 |
| 60–64          | -0.066 | 0.005 | <0.001 | -0.054 | 0.004 | <0.001 |
| 65–69          | -0.071 | 0.005 | <0.001 | -0.060 | 0.004 | <0.001 |

* Adjusted by sex and lipid-lowering treatment.

https://doi.org/10.1371/journal.pone.0260229.t003
On the other hand, our study has also several important strengths. A single measurement of CVD risk factors is not sufficiently precise for estimating life-long disease risk [18, 19]. Baseline measurement of blood lipids as a CVD risk factor is prone to variations associated with factors such as age, lifestyle changes (mainly physical activity and dietary habits) and seasonal variability; e.g. in the case of total and LDL-C, fluctuations of more than 1 mmol/L between summer and winter seasons have been reported [20]. Thus, single measurements can be misleading, resulting in the misclassification of subjects into at-risk groups. Alternative models are now being used to improve risk estimation [21], such as variable categorisation of linear modelling. The analysis of trajectories from more than two individual measurements seems to offer more precise estimates for risk prediction [21, 22]. Supportive evidence is provided by recent Mendelian randomisation studies of lifetime risk of CVD [23, 24]. In UK Biobank study, Ference et al., using score of genetic variants associated with lower LDL-C levels as instrument of randomization, reported strong association between lifelong genetic exposure to lower levels of LDL-C and lower cardiovascular risk [23]. Swedisch study [24] than suggest, that LDL-C is is related with myocardial infarction, but not with stroke or heart failure.

Importantly, this large cohort study models long-term trajectories of lipids in correlation with advancing age. To the best of our knowledge, no similar study has focused on lipid trajectories within the Russian population (a group on which there is a significant lack of epidemiological data) or anywhere in Central or Eastern Europe. Thus, our study goes some way to redressing this deficit in knowledge of plasma lipids in this large region. In addition to

---

Table 4. Baseline total cholesterol, LDL-C, HDL-C and triglycerides (intercept) and change in LDL-C, HDL-C and triglycerides per year (slope) in the 5-yr cohorts (* multivariable adjusted).

| Age range in W1 | TC | LDL-C |
|-----------------|-----------------|-----------------|
| Intercept       | Estimate (mmol/l) | 45–49 (ref)     |
| Difference      | coeff. | SE | p-value | coeff. | SE | p-value |
| 45–49 (ref)     | 5.35 | 0.058 | <0.001 | 3.37 | 0.052 | <0.001 |
| 50–54           | 0.228 | 0.043 | <0.001 | 0.190 | 0.038 | <0.001 |
| 55–59           | 0.354 | 0.042 | <0.001 | 0.284 | 0.038 | <0.001 |
| 60–64           | 0.520 | 0.045 | <0.001 | 0.445 | 0.040 | <0.001 |
| 65–69           | 0.482 | 0.045 | <0.001 | 0.420 | 0.040 | <0.001 |

| Age range in W1 | HDL-C | TG |
|-----------------|-----------------|-----------------|
| Intercept       | Estimate (mmol/l) | 45–49 (ref)     |
| Difference      | coeff. | SE | p-value | coeff. | SE | p-value |
| 45–49 (ref)     | 1.47 | 1.11 | 1.11 | 1.11 | 0.052 | <0.001 |
| 50–54           | 0.020 | 0.059 | 0.059 | 0.059 | 0.038 | <0.001 |
| 55–59           | 0.021 | 0.098 | 0.098 | 0.098 | 0.038 | <0.001 |
| 60–64           | 0.014 | 0.131 | 0.131 | 0.131 | 0.040 | <0.001 |
| 65–69           | 0.017 | 0.094 | 0.094 | 0.094 | 0.040 | <0.001 |

* Adjusted by sex, lipid-lowering treatment, smoking, BMI, alcohol intake, education, marital status, CVD mortality, all-cause mortality.

https://doi.org/10.1371/journal.pone.0260229.t004
measuring traditional lipids, we also examined non-HDL-C, currently defined as the most relevant atherogenic lipid marker [25].

Together with smoking, diabetes, hypertension and obesity, plasma lipid values (especially total and LDL-cholesterol values) have long been considered as a key modifiable risk factor for atherosclerosis and cardiovascular disease. As observed in the WHO MONICA and post-MONICA studies, plasma lipid values have declined substantially over recent decades due to...
the wide use of statins and the adoption of positive lifestyle changes [26, 27]. In turn, this trend has led to changes in cardiovascular disease and mortality prediction [28–31]. The significant decline in plasma cholesterol values across age groups is consistent with the smaller effect of plasma cholesterol on CVD risk at older ages compared to younger groups. The reasons for the decline in levels of major lipids with age in the Russian population are not easily explained. As mentioned above, the decline appears to be largely treatment-independent. Lifestyle data on dietary habits and physical activity may provide some clues. For instance, the Russian diet is typically higher in energy and lower in vegetable and fruit intake compared to the Western European diet [32, 33], while physical activity in the Russian
population is relatively comparable to both Western and Eastern European populations [Mal-
yutina et al., unpublished data]. Unfortunately, available data about dietary habits and/or gen-
eral physical activities of examined subjects were not known in sufficient details to perform adequate analyses of effects.

While cross-sectional decline in lipids with age in elderly has been widely reported in the literature [6–8], analyses of long-term individual-level trajectories charting the development of lipid parameters remain scarce. One of the first analyses was reported in the Framingham Heart Study [34]. Similar trajectories have been reported by Swiger et al. [35], who describe an age-related decline in LDL-C in subjects over 60 years of age. Our results are in agreement with these studies. According to the findings of National Health and Nutrition Examination Surveys [36], age-related decline may contribute to the decreased cholesterol levels seen in the population over recent decades.

The individual-level decline in blood lipid values in older subjects observed in our longitudi-
nal study reflects similar trends documented in cross-sectional studies [36, 37]. Our findings are consistent with the ARIC Study, which followed up a sample population comprising 9,328 subjects of European ancestry over 9 years. The authors observed an overall decrease in TC and LDL-C levels, a relative stabilisation in HDL-C levels, and a consistent rise in plasma TG values [8]. Similar patterns were very recently reported in 35-year follow-up of Framingham Offspring participants using the group modelling technique [11].

In contrast to TC and LDL-C, trajectories of serum TG levels in our cohorts varied substan-
tially between age groups. Generally, we observed an increase in serum TG values in younger age groups, a plateau in the 55-59-years age category, followed by a decline in subjects over 60 years of age. This is consistent with the recent suggestions that serum TG and TG-rich rem-
nant particles and non-HDL-C might be more powerful for predicting CVD and total mortal-
ity than TC or LDL-C [37]. Based on our previous observations of another geographically identical population (the Novosibirsk MONICA cohort), high TG values significantly increased the 10-year risk of CVD outcomes in men and, especially, women [38].

We have observed an effect of smoking status on lipid trajectories. While TC values were similar in smokers and never smokers, with both groups showing similar decreasing slopes, HDL-C was higher at baseline among smokers but decreased faster, so that at the end of the follow up HDL-C became higher among never-smokers. TG values where higher in ever-
smokers in comparison with never-smokers, and the observed declining trajectory was steeper in never-smokers.

There were some differences between men and women in lipid trajectories. In general, the trajectories in males were steeper than in females. Revealingly, in the youngest age category, the trajectories of LDL-C/HDL-C ratios were significantly higher in males than in females, but no differences between males and females were observed for the highest age category.

An important finding of this study is the parallel decline of serum total and LDL-C in both treatment-naïve and statin-treated subjects. Although the declining slope was, as expected, slightly steeper in treated subjects, it does not seem that the decline in total and LDL choles-
terol in the whole population can be attributed exclusively to lipid-lowering drugs. The use of statins, the major lipid–lowering drug group, increased from 17.9% to 19% in entire population (from 23.8% to 47.1% among those aware of dyslipidaemia). Interestingly, there were no subjects on ezetimibe or PCSK9 inhibitors, as on the most powerful lipid lowering drug known so far, included. The treatment with other lipid-lowering drugs has been negligible (around 1%).

The steeper decline trajectories among subjects treated with lipid lowering drugs compared to those not treated in our sample are consistent with the patterns recently shown by Duncan et al. [10] in Framingham Offspring Study. In the groups composed from individuals with
initially elevated level of TC, LDL-C and non-HDL-C which were decreasing with age, the proportion of lipid lowering treatment was the highest.

Conclusions

In this study in older Russians using the multilevel modelling of longitudinal lipid trajectories, we observed substantial declines in total cholesterol and LDL-C over time and with age. The pattern of declining concentrations does not seem to be attributable solely to lipid-lowering treatment and/or smoking behaviour. On the whole, elderly people seems to be at lower risk of suffering from dyslipidaemia, and gender differences become smaller with increasing age. Longitudinal trajectories of blood lipids from middle to the elderly age may improve prediction of CVD risk beyond using single occasion measurements and may improve the quantification of lifetime exposure to blood lipid concentrations.

Supporting information

S1 Table. Complete cases of all three waves (N = 2009). Baseline total cholesterol, LDL-C, HDL-C and triglycerides (intercept) and change in LDL-C, HDL-C and triglycerides per year (slope) in the 5-yr cohorts (unadjusted).

S2 Table. Complete cases of all three waves (N = 2009). Baseline total cholesterol, LDL-C, HDL-C and triglycerides (intercept) and change in LDL-C, HDL-C and triglycerides per year (slope) in the 5-yr cohorts. Adjusted by sex, lipid-lowering treatment, smoking, BMI, alcohol, education, marital status, CVD mortality, all causes mortality.

S3 Table. Selected sample after exclusion of subjects dropped out after baseline examination and did not die during follow-up (N = 7,606). Baseline total cholesterol, LDL-C, HDL-C and triglycerides (intercept) and change in LDL-C, HDL-C and triglycerides per year (slope) in the 5-yr cohorts (unadjusted).

S4 Table. Selected sample after exclusion of dropped out after baseline examination and did not die during follow-up (N = 7,606). Baseline total cholesterol, LDL-C, HDL-C and triglycerides (intercept) and change in LDL-C, HDL-C and triglycerides per year (slope) in the 5-yr cohorts. Adjusted by sex, lipid-lowering treatment, smoking, BMI, alcohol, education, marital status, CVD mortality, all causes mortality.

S1 Fig. TC trajectories in men and women over the 12 years of follow up.

S2 Fig. LDL-C trajectories in men and women over the 12 years of follow up.

S3 Fig. HDL-C trajectories in men and women over the 12 years of follow up.

S4 Fig. TG trajectories in men and women over the 12 years of follow up.

S5 Fig. Non HDL-C trajectories in men and women over the 12 years of follow up.
S6 Fig. Ratio LDL/HDL trajectories in men and women over the 12 years of follow up. (DOCX)

S7 Fig. TC trajectories in men and women over the 12 years of follow up by smoking. (DOCX)

S8 Fig. LDL-C trajectories in men and women over the 12 years of follow up by smoking. (DOCX)

S9 Fig. HDL-C trajectories in men and women over the 12 years of follow up by smoking. (DOCX)

S10 Fig. TG trajectories in men and women over the 12 years of follow up by smoking. (DOCX)

S11 Fig. NonHDL-C trajectories in men and women over the 12 years of follow up by smoking. (DOCX)

S12 Fig. Ratio LDL/HDL trajectories in men and women over the 12 years of follow up by smoking. (DOCX)

S13 Fig. TC trajectories in men and women over the 12 years of follow up by lipid lowering treatment. (DOCX)

S14 Fig. LDL-C trajectories in men and women over the 12 years of follow up by lipid lowering treatment. (DOCX)

S15 Fig. HDL-C trajectories in men and women over the 12 years of follow up by lipid lowering treatment. (DOCX)

S16 Fig. TG trajectories in men and women over the 12 years of follow up by lipid lowering treatment. (DOCX)

S17 Fig. nonHDL-C trajectories in men and women over the 12 years of follow up by lipid lowering treatment. (DOCX)

S18 Fig. Ratio LDL/HDL trajectories in men and women over the 12 years of follow up by lipid lowering treatment. (DOCX)

**Author Contributions**

**Conceptualization:** Jaroslav A. Hubacek, Michael V. Holmes, Martin Bobak, Sofia Malyutina.

**Data curation:** Yuri Nikitin, Yulia Ragino, Ekaterina Stakhneva, Andrey Ryabikov, Eugeny Verevkin.

**Formal analysis:** Hynek Pikhart, Denes Stefler, Eugeny Verevkin, Sofia Malyutina.

**Funding acquisition:** Martin Bobak, Sofia Malyutina.
**Investigation:** Jaroslav A. Hubacek, Yuri Nikitin, Yulia Ragino, Ekaterina Stakhneva, Martin Bobak, Sofia Malyutina.

**Methodology:** Jaroslav A. Hubacek, Hynek Pikhart, Anne Peasey, Michael V. Holmes, Martin Bobak, Sofia Malyutina.

**Project administration:** Andrey Ryabikov, Eugeny Verevkin, Sofia Malyutina.

**Resources:** Martin Bobak, Sofia Malyutina.

**Supervision:** Jaroslav A. Hubacek, Hynek Pikhart, Anne Peasey, Michael V. Holmes, Denes Stefler, Martin Bobak.

**Visualization:** Sofia Malyutina.

**Writing – original draft:** Jaroslav A. Hubacek.

**Writing – review & editing:** Yuri Nikitin, Yulia Ragino, Ekaterina Stakhneva, Hynek Pikhart, Anne Peasey, Michael V. Holmes, Denes Stefler, Andrey Ryabikov, Eugeny Verevkin, Martin Bobak, Sofia Malyutina.

**References**

1. Roth MD, Johnson C, Abajobir A, Abd-Allah F, Abera SF, Abyu G, et al. Global and regional patterns in cardiovascular mortality from 1990 to 2013. Circulation 2015; 132:1667–1678. https://doi.org/10.1161/CIRCULATIONAHA.114.008720 PMID: 26503749

2. Zeitouni M, Sabouret P, Kerneis M, Silvain J, Collet JP, Bruckert E, et al. 2019 ESC/EAS Guidelines for management of dyslipidaemia: strengths and limitations. Eur Heart J Cardiovasc Pharmaother. 2020; pvaaa077. https://doi.org/10.1093/ehjcvp/pva077

3. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41:111–118. Erratum in: Eur Heart J. 2020;41:4255. https://doi.org/10.1093/eurheartj/ehz455 PMID: 31504418

4. Pollin TI, Quartuccio M. What we know about diet, genes, and dyslipidemia: Is there potential for translation? Curr Nutr Rep. 2013; 2:236–242. https://doi.org/10.1007/s13668-013-0065-z PMID: 24524012

5. Cole CB, Nikpay M, McPherson R. Gene-environment interaction in dyslipidemia. Curr Opin Lipidol. 2015; 26:133–138. https://doi.org/10.1097/MOL.0000000000000160 PMID: 25692343

6. Shkolnikov VM, Andreew EM, Tursun-Zade R, Leon DA. Patterns in the relationship between life expectancy and gross domestic product in Russia in 2005–15: a cross-sectional analysis. Lancet Public Health 2019; 4:e181–e188. https://doi.org/10.1016/S2468-2667(19)30036-2 PMID: 30954143

7. van Vliet P, Westendorp RG, van Heemst D, van Heemst D, de Craen AJ, Oleksik AM. Cognitive decline precedes life-long longitudinal changes in vascular risk factors. J Neurol Neurosurg Psychiatry 2010; 81:1028–1032. https://doi.org/10.1136/jnnp.2009.182519 PMID: 20543187

8. Lutsey PL, Rasmussen-Torvik LJ, Pankow JS, Alonso A, Smolencki DJ, Tang W, et al. Relation of lipid gene scores to longitudinal trends in lipid levels and incidence of abnormal lipid levels among individuals of European ancestry: the Atherosclerosis Risk in Communities (ARIC) study. Circ Cardiovasc Genet. 2012; 5:73–80. https://doi.org/10.1161/CIRCGENETICS.111.959619 PMID: 22057756

9. Upmeier E, Lavonius S, Heinonen P, Viltanen M, Isoaho H, Arve S, et al. Longitudinal changes in serum lipids in older people the Turku elderly study 1991–2006. Age Ageing 2011; 40:280–283. https://doi.org/10.1093/aging/afq180 PMID: 21252037

10. Dayimu A, Wang C, Li J, Fan B, Ji X, Zhang T, et al. Trajectories of lipids profile and incident cardiovascular disease risk: A longitudinal cohort study. J Am Heart Assoc. 2019; 8:e013479. https://doi.org/10.1161/JAHA.119.013479 PMID: 31630587

11. Duncan MS, Vasan RS, Vanessa X. Trajectories of blood lipid concentrations over the adult life course and risk of cardiovascular disease and all-cause mortality: Observations from the Framingham Study over 35 years. J Am Heart Assoc. 2019; 8:e011433. https://doi.org/10.1161/JAHA.118.011433 PMID: 31137992

12. Peasey A, Bobak M, Kubinova R, Malyutina S, Pajak A, Tamosiunas A, et al. Determinants of cardiovascular disease and other non-communicable diseases in Central and Eastern Europe: rationale and
13. Peasey A, Bobak M, Malyutina S, Pajak A, Kubinová R, Pikhart H, et al. Do lipids contribute to the lack of cardio-protective effect of binge drinking: alcohol consumption and lipids in three eastern European countries. Alcohol Alcohol. 2005; 40:431–435. https://doi.org/10.1093/alcalc/agh161 PMID: 15939709

14. Nikitin YP, Makarenkova KV, Malyutina SK, Pajak A, Kubinová R, Peasey A, et al. [Blood lipid parameters in populations of Russia, Poland and Czech Republic: The HAPIEE study]., Article in Russian. Kardiologiya 2015; 55:34–39. https://doi.org/10.18565/cardio.2015.5.34-39

15. Hu Y, Malyutina S, Pikhart H, Peasey A, Holmes MV, Hubacek J, et al. The relationship between body mass index and 10-year trajectories of physical functioning in middle-aged and older Russians: prospective results of the Russian HAPIEE study. J Nutr Health Aging 2017; 21:381–388. https://doi.org/10.1007/s12603-016-0769-z PMID: 28346564

16. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18:499–502. PMID: 4337382

17. Leckie G, Charlton C. runmlwin: a program to run the MLwiN multilevel modeling software from within Stata. J Stat Soft. 2012; 52: https://doi.org/10.18637/jss.v052.i11

18. Paige E, Barrett J, Pennells L, Sweeting M, Willeit P, Di Angelantonio E, et al. Use of repeated blood pressure and cholesterol measurements to improve cardiovascular disease risk prediction: An individual-participant-data Meta-analysis. Am J Epidemiol. 2017; 186:899–907. https://doi.org/10.1093/aje/kwx149 PMID: 28549073

19. Cho IJ, Sung JM, Chang HJ, Chung N, Kim HC. Incremental value of repeated risk factor measurements for cardiovascular disease prediction in middle-aged Korean adults: Results from the NHS-HEALS (National Health Insurance System-National Health Screening Cohort). Circ Cardiovasc Qual Outcomes 2017;10(pi): e004197. https://doi.org/10.1161/CIRCUITCOMES.117.004197 PMID: 29150537

20. Ockene IS, Chiriboga DE, Stanek EJ 3rd, Harmatz MG, Nicolosi R, Saperia G, et al. Seasonal variation in serum cholesterol levels: treatment implications and possible mechanisms. Arch Intern Med. 2004; 164:863–870. https://doi.org/10.1001/archinte.164.8.863 PMID: 15113722

21. Reinkainen J, Laatikainen T, Karvonen J, Tolonen H. Lifetime cumulative risk factors predict cardiovascular disease mortality in a 50-year follow-up studying Finland. Int J Epidemiol. 2015; 44:108–116. https://doi.org/10.1093/ije/dyu235 PMID: 25501686

22. Packard CJ, Weintrob WS, Laufs U. New metrics needed to visualize the long term impact of early LDL-C lowering on the cardiovascular disease trajectory. Vas Pharmacol. 2015; 71:37–39. https://doi.org/10.1016/j.vph.2015.03.008

23. Ference BA, Bhatt DL, Catapano AL, Packard CJ, Graham I, Kaptoge S, et al. Association of genetic variants related to combined exposure to lower low-density lipoproteins and lower systolic blood pressure with lifetime risk of cardiovascular disease. JAMA. 2019;322(32):1381–1391. https://doi.org/10.1001/jama.2019.14120 PMID: 31475726

24. Lind L, Ingelsson M, Sundstrom J, miov J. Impact of risk factors for major cardiovascular diseases: a comparison of life-time observational and Mendelian randomization findings. Open Heart. 2021; 8: e001735. https://doi.org/10.1136/openhrt-2021-001735 PMID: 34518296

25. Su X, Kong Y, Peng D. Evidence for changing lipid management strategies to focus on non-high density lipoprotein cholesterol. Lipids Health Dis. 2019; 18:134. https://doi.org/10.1186/s12944-019-1080-x PMID: 31107977

26. Ellasson M, Janlert U, Jansson JH Stegmayr B. Time trends in population cholesterol levels 1986–2004: influence of lipid-lowering drugs, obesity, smoking and educational level. The northern Sweden MONICA study. J Intern Med. 2006; 260:551–559. https://doi.org/10.1111/j.1365-2796.2006.01790.x PMID: 17116006

27. Cífková R, Bruthans J, Wohlfarth P, Krajičovechová A, Šulc P, Jozífová M, et al. 30-year trends in major cardiovascular risk factors in the Czech population, Czech MONICA and Czech post-MONICA, 1985–2016/17. Plos One 2020; 15:e0232845. https://doi.org/10.1371/journal.pone.0232845 PMID: 32392239

28. Liu J, Zeng FF, Liu ZM, Zhang CX, Ling WH, Chen YM. Effect of blood triglycerides on cardiovascular and all-cause mortality: a systematic review and meta-analysis of 61 prospective studies. Lipids Health Dis. 2013; 12:159. https://doi.org/10.1186/1476-511x-12-159 PMID: 24164719

29. Pikhart H, Hubáček J, Peasey A, Kubinová R, Bobák M. Association between fasting plasma triglycerides, all-cause and cardiovascular mortality in Czech population. Results from the HAPIEE study. Physiol Res. 2015; 64 (Suppl 3):S355–S361. https://doi.org/10.33549/physiores.933179 PMID: 26680668

30. Hubacek JA, Stanek V, Gebauerova M, Adamkova V, Lesauksaitė V, Zaliaduonyte-Peksiene D, et al. Traditional risk factors of acute coronary syndrome in four different male populations—total cholesterol
value does not seem to be relevant risk factor. Physiol Res. 2017; 66 (Suppl 1):S121–S128. https://doi.org/10.33549/physiolres.933597 PMID: 28379037

31. Tamosiunas A, Luksiene D, Baceviciene M, Bernotiene G, Radisauskas R, Malinauskiene V, et al. Health factors and risk of all-cause, cardiovascular, and coronary heart disease mortality: findings from the MONICA and HAPIEE studies in Lithuania. PLoS One 2014; 9:e114283. https://doi.org/10.1371/journal.pone.0114283 PMID: 25479610

32. Stefler D, Bobak M. Does the consumption of fruits and vegetables differ between Eastern and Western European populations? Systematic review of cross-national studies. Arch Public Health 2015; 73:29. https://doi.org/10.1186/s13690-015-0078-8 PMID: 26078867

33. Stefler D, Pikhart H, Jankovic N, Kubinova R, Pajak A, Malyutina S, et al. Healthy diet indicator and mortality in Eastern European populations: prospective evidence from the HAPIEE cohort. Eur J Clin Nutr. 2014; 68:1346–1352. https://doi.org/10.1038/ejcn.2014.134 PMID: 25028084

34. Abbott RD, Garrison RJ, Wilson PW, Epstein FH, Castelli WP, Feinleib M, et al. Joint distribution of lipoprotein cholesterol classes. The Framingham study. Arteriosclerosis 1983; 3:260–272. https://doi.org/10.1161/ATVBAHA.116.307601 PMID: 27515380

35. Swiger KJ, Martin SS, Blaha MJ, Toth PP, Nasir K, Michos ED, et al. Narrowing sex differences in lipoprotein cholesterol subclasses following mid-life: the very large database of lipids (VLDL-10B). J Am Heart Assoc, 2014; 3:e000851. https://doi.org/10.1161/JAHA.114.000851 PMID: 24755154

36. Carroll MD, Kit BK, Lacher DA, Shero ST, Mussollino ME. Trends in lipids and lipoproteins in US adults, 1988–2010. JAMA 2012; 308:1545–1554. https://doi.org/10.1001/jama.2012.13260 PMID: 23073951

37. Puri R, Nissen SE, Shao M, Elshazly MB, Kataoka Y, Kapadia SR, et al. Non-HDL cholesterol and triglycerides: Implications for coronary atheroma progression and clinical events. Arterioscler Thromb Vasc Biol. 2016; 36:2220–2228. https://doi.org/10.1161/ATVBAHA.116.307601 PMID: 27515380

38. Malyutina SK, Simonova GI, Nikitin YuP. The incidence of coronary heart disease and cardiovascular mortality in the urban Siberian population: Gender specific findings from the 10-year cohort study. In: Heart Disease: Environment, Stress and Gender. (Eds. Weidner G., Kopps M., Kristensen M.) NATO Science Series, Series I: Life and Behavioral Sciences. - 2000.—Vol. 327:p. 69–79.